Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.74 |
| ▸ | ADH1A | P07327 | 4/20 | 0.74 |
| ▸ | ADH1C | P00326 | 3/20 | 0.59 |
| ▸ | ADH7 | P40394 | 2/20 | 0.59 |
| ▸ | ADH4 | P08319 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17690614 | 1.00 | ADH1B (0.74) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17690667 | 1.00 | ADH1B (0.74) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL19658308 | 0.86 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL115609 | 0.86 | — | — | |
| SCHEMBL21997344 | 0.86 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL20678957 | 0.85 | — | — | |
| SCHEMBL18924689 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL4095046 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL9205102 | 0.83 | — | — | |
| Bicarbonate SCHEMBL11031476 | 0.81 | ADH1B (0.78) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-2707372-B1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | UNIV MICHIGAN REGENTS (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3040333-A1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | Novartis AG (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016032882-A1 | INHIBITION OF MK2 IN THE TREATMENT OF CANCER | STC.UNM (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| CN-104987321-A | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG | 2015-10-21 | — | — | CN | disclosed |
| EP-0706532-B1 | Peptides having endothelin antagonictic activity,their preparation and pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
| US-5888972-A | ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0706532-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-17 | — | — | EP | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| WO-1995000537-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | ADH1B 2314/4885ADH1A 2829/4885ADH1C 1959/4885 |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | ADH1B 510/4885ADH1A 1366/4885ADH1C 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.